SOLV Stock Summary and Trading Ideas (Solventum | NYSE:SOLV)

In spring 2024, 3M spun out its legacy healthcare segment as a stand-alone firm, Solventum. At that time, the firm comprised four segments. The smallest one—purification and filtration—has since been sold. Now, medsurg is the largest business, contributing roughly 64% of consolidated revenue, and includes advanced wound care and wound prevention. Dental solutions (restorative composites and orthodontia) and health information systems (mainly revenue cycle management) each contribute 18% of total revenue.

Solventum trades on the NYSE stock market under the symbol SOLV.

As of September 9, 2026, SOLV stock price declined to $90.03 with 731,519 million shares trading.

SOLV has a beta of 0.42, meaning it tends to be less sensitive to market movements. SOLV has a correlation of 0.03 to the broad based SPY ETF.

SOLV has a market cap of $15.33 billion. This is considered a Large Cap stock.

Last quarter Solventum reported $2 billion in Revenue and $2.55 earnings per share. This beat revenue expectation by $47 million and exceeded earnings estimates by $.65.

The top ETF exchange traded funds that SOLV belongs to (by Net Assets): VTI, VOO, VB, RSP, VBR.

SOLV has outperformed the market in the last year with a return of +20.7%, while the SPY ETF gained +18.7%. In the last 3 month period, SOLV beat the market returning +14.3%, while SPY returned +3.4%. However, in the most recent 2 weeks SOLV has underperformed the stock market by returning -1.7%, while SPY returned -0.5%.

SOLV support price is $88.51 and resistance is $91.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SOLV shares will trade within this expected range on the day.